Systemic lupus erythematosus secondary prevention: Difference between revisions
| Line 8: | Line 8: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
* Prevent glucocorticoid usage and use the minimum dosage to prevent osteonecrosis and osteoprosis side effects<ref name="pmid10782816">{{cite journal |vauthors=Zangger P, Gladman DD, Urowitz MB, Bogoch ER |title=Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus |journal=J. Rheumatol. |volume=27 |issue=4 |pages=919–23 |year=2000 |pmid=10782816 |doi= |url=}}</ref> | * Prevent [[glucocorticoid]] usage and use the minimum dosage to prevent [[osteonecrosis]] and osteoprosis side effects<ref name="pmid10782816">{{cite journal |vauthors=Zangger P, Gladman DD, Urowitz MB, Bogoch ER |title=Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus |journal=J. Rheumatol. |volume=27 |issue=4 |pages=919–23 |year=2000 |pmid=10782816 |doi= |url=}}</ref> | ||
* Decrease atherosclerotic events in patients | * Decrease [[Atherosclerosis|atherosclerotic]] events in patients | ||
** Low doses of aspirin | ** Low doses of [[aspirin]] | ||
** ACE inhibitors | ** [[ACE inhibitor|ACE inhibitors]] | ||
** Statins | ** [[Statins]] | ||
* For prevention and/or early diagnosis of malignancies: | * For prevention and/or early diagnosis of [[malignancies]]: | ||
** Regular age-related specific cancer screening recommended for the general population | ** Regular age-related specific [[cancer screening]] recommended for the general population | ||
==References== | ==References== | ||
Revision as of 13:30, 6 July 2017
|
Systemic lupus erythematosus Microchapters |
|
Differentiating Systemic lupus erythematosus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Systemic lupus erythematosus secondary prevention On the Web |
|
American Roentgen Ray Society Images of Systemic lupus erythematosus secondary prevention |
|
Systemic lupus erythematosus secondary prevention in the news |
|
Directions to Hospitals Treating Systemic lupus erythematosus |
|
Risk calculators and risk factors for Systemic lupus erythematosus secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Overview
Secondary prevention strategies following systemic lupus erythematosus include using aspirin, ACE inhibitors, and statins to reduce atherosclerotic diseases, and using cancer screenings.
Secondary Prevention
- Prevent glucocorticoid usage and use the minimum dosage to prevent osteonecrosis and osteoprosis side effects[1]
- Decrease atherosclerotic events in patients
- Low doses of aspirin
- ACE inhibitors
- Statins
- For prevention and/or early diagnosis of malignancies:
- Regular age-related specific cancer screening recommended for the general population